Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the specific claim about complex sleep behaviors is supported by the provided label excerpt (section 5.1). The remaining claims are largely not evaluated against label text because the provided FDA label content in the prompt does not include information needed to verify them (e.g., manufacturer, generic pricing/availability, exact side effects list, dependence/warnings details, and short-term duration).
Category Scores
Accurate Statements
Complex sleep behaviors (e.g., sleep-walking, sleep-driving, and engaging in other activities while not fully awake) may occur after use of AMBIEN; discontinuation is recommended if a patient experiences a complex sleep behavior.
Supported by labeling section 5.1 (WARNING: Complex Sleep Behaviors), which states these behaviors may occur and to discontinue AMBIEN immediately if a patient experiences a complex sleep behavior.
Unsupported Statements
Ambien is the brand name for zolpidem tartrate.
The provided label excerpts in the prompt do not explicitly state this equivalence in a way that can be directly verified from the included text.
Ambien is used for the short-term treatment of insomnia.
The prompt includes indication text, but the provided evaluation focuses only on the single complex sleep behaviors claim; the remaining claims are not supported by explicitly provided excerpts for verification in the evaluation output.
Ambien is a sedative-hypnotic medication that works by slowing down activity in the brain to allow sleep.
Mechanism of action in the provided text describes GABA-A receptor positive modulation and neuronal excitation inhibition; it does not support the phrasing 'slowing down activity in the brain.'
Ambien is manufactured by Sanofi-Aventis.
Manufacturer is not present in the provided label excerpts.
The generic form of Ambien is zolpidem tartrate.
Generic equivalence is not explicitly stated in the provided label excerpts.
Generic versions of the brand-name drug are typically available once the brand-name drug's patent expires.
Patent-expiration timing is not addressed in the provided label excerpts.
Generic versions are usually less expensive than the brand-name drug.
Pricing/expense comparisons are not addressed in the provided label excerpts.
Common side effects of Ambien can include drowsiness, dizziness, and diarrhea.
The provided label excerpts do not include a 'common side effects' list or support diarrhea as a side effect.
Ambien is intended for short-term use, generally for one to two weeks.
The provided indication text states 'short-term treatment' and mentions sleep latency decrease up to 35 days; it does not support 'one to two weeks.'
Prolonged use of Ambien can lead to dependence.
While dependence/withdrawal are referenced in the provided excerpts, the claim is not supported with the specific 'prolonged use' framing in the provided evaluation output.
A physical and psychological dependence on zolpidem can develop even at recommended dosages.
The provided excerpts include monitoring for tolerance/abuse/dependence but do not support this exact statement as written in the provided text.
Withdrawal symptoms can occur if zolpidem is stopped abruptly after prolonged use.
Label excerpt supports withdrawal signs/symptoms after rapid dose decrease or abrupt discontinuation, but does not support 'after prolonged use' as a required condition.
Risks associated with Ambien include next-day impairment.
The provided excerpt includes next-day impairment/psychomotor impairment risk, but the evaluation output does not explicitly verify this additional claim against a cited label section.
Risks associated with Ambien include complex sleep behaviors such as sleep-walking or sleep-driving.
This is supported by section 5.1, but the prompt’s evaluation output only directly verifies the single complex sleep behaviors claim; the broader list may not be explicitly tied to the same verification.
Risks associated with Ambien include potential for abuse and dependence.
The provided excerpt includes monitoring for tolerance/abuse/dependence, but the evaluation output does not explicitly verify this exact phrasing against a cited section.
Contradictions
Important Omissions
For claims about dependence/withdrawal, the label excerpt emphasizes monitoring for tolerance, abuse, and dependence and notes withdrawal signs/symptoms after rapid dose decrease or abrupt discontinuation; the evaluation output does not assess whether the other dependence/withdrawal claims match the label wording exactly.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements (e.g., duration 'one to two weeks,' mechanism phrasing, specific adverse effects list including diarrhea, and dependence framing 'prolonged use') are not supported by the provided label excerpts in the prompt, which could lead to inaccurate labeling interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Only the complex sleep behaviors/discontinue instruction claim is explicitly supported by the provided label excerpt; multiple other claims are not verified against the supplied label text or are phrased in ways not supported by the excerpt.
Suggested Improvement
Evaluate each claim against the specific sections of the provided label excerpts and restrict statements to language supported by those excerpts (e.g., avoid unsupported 'one to two weeks' timeframe and avoid unverified adverse effect lists/pricing/manufacturer statements).